Shares of InflaRx N.V. (NASDAQ:IFRX – Get Free Report) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.00.
IFRX has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Oppenheimer initiated coverage on InflaRx in a research report on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $14.00 target price on shares of InflaRx in a research report on Tuesday, April 21st. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $7.00 to $9.00 in a research report on Wednesday.
View Our Latest Research Report on InflaRx
InflaRx Price Performance
InflaRx (NASDAQ:IFRX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. Research analysts expect that InflaRx will post -0.51 earnings per share for the current year.
Institutional Investors Weigh In On InflaRx
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC grew its position in InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after purchasing an additional 17,056 shares during the period. ADAR1 Capital Management LLC acquired a new stake in InflaRx during the 3rd quarter worth about $214,000. Susquehanna International Group LLP acquired a new stake in InflaRx during the 3rd quarter worth about $190,000. XTX Topco Ltd acquired a new stake in InflaRx during the 4th quarter worth about $135,000. Finally, Quadrature Capital Ltd acquired a new stake in InflaRx during the 4th quarter worth about $104,000. 42.39% of the stock is owned by institutional investors and hedge funds.
About InflaRx
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
Featured Articles
- Five stocks we like better than InflaRx
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
